Plasmid Display for Stabilization of Enzymes Inside the Cell to Improve Whole-Cell Biotransformation Efficiency

Yunjeong Park 1†, Jonghyeok Shin 1†, Jinkyung Yang 1†, Hooyeon Kim 1, Younghun Jung 1, Hyunseok Oh 1, Yongjoon Kim 1, Jaehyeon Hwang 1, Myeongseo Park 1, Choongjin Ban 1,2, Ki Jun Jeong 3, Sun-Ki Kim 4* and Dae-Hyuk Kweon 1,2,5*

1 Department of Integrative Biotechnology, College of Biotechnology and Bioengineering, Sungkyunkwan University, Suwon-si, South Korea, 2 Institute of Biomolecule Control, Sungkyunkwan University, Suwon-si, South Korea, 3 Department of Chemical and Biomolecular Engineering, KAIST, Daejeon, South Korea, 4 Department of Food Science and Technology, Chung-Ang University, Anseong, South Korea, 5 Institute of Biologics, Sungkyunkwan University, Suwon-si, South Korea

Recombinant whole-cell biocatalysts are widely used for biotransformation of valuable products. However, some key enzymes involved in biotransformation processes are unstable and cannot be easily expressed in the functional form. In this study, we describe a versatile platform for enzyme stabilization inside the cell: Intracellularly Immobilized Enzyme System (IIES). A 1,2-fucosyltransferase from Pedobacter saltans (PsFL) and a 1,3-fucosyltransferase from Helicobacter pylori (HpFL), chosen as model proteins, were fused with Oct-1 DNA-binding domain, which mediated the formation of a plasmid-protein complex. Oct-1 fusion enabled both soluble and stable expression of recombinant proteins in the cytoplasm because the fusion proteins were stabilized on the plasmid like immobilized enzymes bound to solid surface. As a result, Oct-1-fusion proteins exhibited significantly greater product titer and yield than non-fusion proteins. Use of fusion proteins PsFL-Oct-1 with C-terminal Oct-1 and Oct-1-PsFL with N-terminal Oct-1 resulted in ∼3- and ∼2-fold higher 2′-fucosyllactose titers, respectively, than with the use of PsFL alone. When Oct-1 was fused to HpFL, which requires dimerization through heptad repeats, almost two times more 3-fucosyllactose was produced. Fucosyllactose has been used as a food additive because it has various beneficial effects on human health. We anticipate that IIES using Oct-1 fusion protein developed in this study can be applied to stabilize other unstable enzymes.

Keywords: Oct-1, DNA binding protein, intracellularly immobilized enzyme system, Escherichia coli, whole-cell biotransformation

INTRODUCTION

Escherichia coli is generally the first choice of host for the production of proteins and chemicals, because of its fast growth rate, a well-established expression system, high production yield, and low manufacturing cost. In E. coli cytoplasm, however, recombinant proteins tend to interact with non-specific hydrophobic patches, leading to the formation of inclusion bodies (Baneyx and Mujacic, 2004). To enhance soluble expression of recombinant proteins, various strategies
have been suggested: N-terminus and/or C-terminus truncation, co-expression of chaperones, and fusion protein technologies (Sorensen and Mortensen, 2005). To date, Schistosoma japonicum glutathione S-transferase (GST), *E. coli* maltose-binding protein (MBP), *E. coli* N-utilization substance A (NusA), and *E. coli* thioredoxin are commonly used as fusion partners to prevent inclusion body formation (Esposito and Chatterjee, 2006). Although fusion partners provide a general protective effect against insoluble aggregation, some soluble fusions lack detectable activities (Sachdev and Chirgwin, 1999). These soluble aggregates are formed by agglomeration of misfolded proteins of interest, while precipitation is prevented by the presence of the soluble fusion partners (Nomine et al., 2001). Thus, an alternative fusion system should be developed to increase soluble expression levels and simultaneously block agglomeration formation between misfolded target proteins.

As model proteins, we chose two fucosyltransferases (FTs). FTs transfer the fucosyl residue of GDP-L-fucose to lactose, leading to the formation of fucosylated human milk oligosaccharides (HMOs). Microbial production of HMOs has received great attention, as they show beneficial effects on human health, such as prevention of pathogenic infection, modulation of the immune system, and prebiotic effects (Bode, 2015). Among various HMOs present, almost half are fucosylated, and the most abundantly present fucosylated HMOs are 2′-fucosyllactose (Fuc-α1,2-Gal-β1,4-Glc; 2′-FL) and 3-fucosyllactose (Gal-β1,4-(Fuc-α1,3)-Glc; 3-FL) (Thurl et al., 2010). Although all 1,2-FTs are monomers and their activities are related to intrinsic solubility, all 1,3-FTs contain various lengths of heptad repeats mediating dimerization, which is crucial for substrate binding (Sun et al., 2007). Thus, 1,2-, and 1,3-selective FTs were included as the model proteins, not only because the final products are important but also because their structural architectures are very distinct from each other. However, the reactions catalyzed by FTs have been recognized as limiting steps because these enzymes are hardly expressed in a functional form and are rather unstable under process conditions (Chin et al., 2015; Choi et al., 2016; Yu et al., 2018).

Enzyme immobilization provides an effective way to circumvent the concerns related to aggregation, by improving enzyme stability against temperature, solvents, pH, and impurities (Sheldon, 2007; Xie et al., 2009). Also, enzyme immobilization allows reutilization of biocatalyst and hence reduces the cost of biocatalyst production. Although the *in vitro* technology of enzyme immobilization has been intensively studied, protein engineering efforts to immobilize enzymes *in vivo* have been few (Steinmann et al., 2010). Therefore, we sought to develop a system in which the target enzyme is synthesized by *E. coli* and simultaneously immobilized to the surface of a stable molecule that is produced by *E. coli*. Because DNA is a very stable molecule in *E. coli* cytoplasm, the enzyme of interest can be potentially stabilized if the enzyme is attached to plasmids. Recently, a plasmid display system using human Oct-1 DNA-binding domain (DBD) was successfully developed (Park et al., 2013). Human Oct-1 is a transcription factor involved in the regulation of various housekeeping genes (Segel et al., 1991). Oct-1 DBD consists of an N-terminal POU-specific domain, a short flexible linker, and a C-terminal POU homeodomain. Although each domain does not have high binding affinity of each domain to target DNA binding sequences (BS, 5′-ATGCAAAT-3′) is not high enough, Oct-1 DBD can bind to BS with high affinity (Kₚ = 9 × 10⁻¹¹ M) via cooperative binding of both domains (Klemm and Pabo, 1996). Moreover, Oct-1 DBD itself exhibited both high expression level and high solubility (Park et al., 2013). These results suggest that Oct-1 DBD is a good fusion tag to demonstrate intracellularly immobilized enzyme system (IIES) among other DBDs with their relatively large size, or complex structures that are difficult to produce in the cytoplasm of *E. coli* (Yesudhas et al., 2017). Furthermore, we found that Oct-1 DBD binds non-specifically to DNA without BS, enabling to overcome potential stoichiometric mismatch between the number of BS and the number of expressed fusion proteins. In this study, a novel whole-cell biotransformation process with IIES was developed to enhance production yield of 2′-FL and 3-FL, whose production was catalyzed by *Pedobacter saltans* 1,2-FT (PsFL) and *Helicobacter pylori* 1,3-FT (HpFL), respectively.

## MATERIALS AND METHODS

### Strains and Plasmids

All the strains and plasmids used in this study are listed in Table 1. All cloning experiments were performed using a ligation-independent cloning method with T4 DNA polymerase (New England Biolabs). The PCR amplification with Q5 High Fidelity DNA Polymerase (New England Biolabs) was set as initial denaturation step at 98°C for 30 s, followed by 35 repetitions of the following cycle: denaturation step, 98°C, 10 s; annealing step, 50~55°C, 30 s; and elongation step, 72°C, 30 s/kb. The final step took place at 72°C for 2 min. Plasmids pOct-1-PsFL, pPsFL-Oct-1, pBSx-Oct-1-PsFL, and pBSx-PsFL-Oct-1 were constructed as shown in Supplementary Figures 1, 2. Plasmid pOct-1-PsFL was constructed in five cloning steps. First, a DNA fragment coding for Oct-1 DBD was amplified with primers pCOLA-Oct-1 I FW and pCOLA-Oct-1 I BW using human cDNA as the template. This DNA fragment combined with a linearized plasmid pCOLADuet-1 amplified with primers pCOLA-Oct-1 I V FW and pCOLA-Oct-1 I BW using human cDNA as the template. The final DNA fragment containing with a linearized plasmid pCOLADuet-1 amplified with primers pCOLA-Oct-1 I V FW and pCOLA-Oct-1 I V BW to construct pCOLA-Oct-1 I V. Second, Plasmid pBS3-Oct-1 is identical to pCOLA-Oct-1 except that it contains 3 repeats of the Oct-1-specific DNA binding sequence (3 OBS). To make this change, a DNA fragment containing pCOLA-Oct-1 was amplified with primers pCOLA-BS FW and pCOLA-BS BW to be combined by T4 DNA polymerase. Third, a DNA fragment coding for PsFL was amplified with primers pCOLA-Oct-1 PsFL I FW and pCOLA-Oct-1 PsFL I BW using pCOLA-PsFL (AP Technology, Suwon, Republic of Korea) as the template. A DNA fragment containing Oct-1 DBD and 3 OBS was amplified with primers pCOLA-Oct-1 PsFL V FW and pCOLA-Oct-1 PsFL V BW using PsFL-Oct-1 I V as the template. These two linear DNA fragments were combined using T4 DNA polymerase to construct pOct-1-PsFL intermediate. In a fourth step, pCOLADuet-1 was amplified with primers pCOLA-BS FW and pCOLA-BS BW to construct pCOLA-BS3 by introducing 3 OBS. In the last step, the expression cassette coding for Oct-1-PsFL located in multiple cloning site
TABLE 1 | E. coli strains and plasmids used in this study.

| Name                  | Description                                                                 | Reference                      |
|-----------------------|------------------------------------------------------------------------------|--------------------------------|
| E. coli               |                                                                              |                                |
| TOP10                 | F− mcrA Δ[mrr-bsdRMS-mcrBC] φ80lacZ ΔM15 ΔlacY74 recA1 araD139 Δ[ara- leu/7697 galU gaK] ropL (Streptomycin resistance) endA1 nupG | Invitrogen                     |
| BL21(DE3)             | F− ompTlon hsdS(rK, mC) gal dcm                                              | New England Biolabs            |
| ΔL M15                | BL21star (DE3) ΔlacZYA Tn7- lacZΔM15YA                                        | Chin et al., 2015              |
| Plasmids              |                                                                              |                                |
| pCOLADuet-1           | Two T7 promoters, ColA rep/clon, KanR                                        | Novagen                        |
| pBCGw                 | pETDuet-1 + manC-manB (Ncol/Sacl) + gmd-wcaG (Ndel/KpnI)                      | Lee et al., 2009               |
| pCOLA-PsFl            | pCOLADuet-1 + WT 1,2,FT from P. Sattans                                       | AP Technology                  |
| pCOLA-HpFl            | pCOLADuet-1 + WT 1,3,FT from H. Pylori                                       | Yu et al., 2018                |
| pCOLA-Oct-1           | pCOLADuet-1 + Oct-1 from human                                              | In this study                  |
| pBS3-Oct-1            | pCOLA-Oct-1 + 3 repeats of the Oct-1 specific DNA binding sequence            | In this study                  |
| pOct-1-PsFl           | Intermediate plasmid containing                                              | In this study                  |
| Intermediate          | Oct-1-PsFl expression cassette                                              | In this study                  |
| pPsFL-Oct-1           | pCOLADuet-1 + 3 repeats of the Oct-1 specific DNA binding sequence            | In this study                  |
| pOct-1-PsFl           | pCOLA-Bs3 + Oct-1-PsFl                                                       | In this study                  |
| pPsFL-Oct-1           | pCOLA-Bs3 + PsFl-Oct-1                                                       | In this study                  |
| pBSx-Oct-1-PsFl       | pCOLADuet-1 + Oct-1-PsFl                                                     | In this study                  |
| pBSx-PsFL-Oct-1       | pCOLADuet-1 + Oct-1-PsFl                                                     | In this study                  |
| pOct-1-HpFl           | pCOLA-Bs3 + Oct-1-HpFl                                                       | In this study                  |
| pHps-Oct-1-G          | pCOLA-Bs3 + HpFl-Oct-1                                                       | In this study                  |

was constructed by replacing PsFL of pPsFL-Oct-1 with HpFL, as described above. The primer sets used for amplification of the two DNA fragments are as follows: pCOLADuet-POI-Oct-1 V FW and pCOLADuet-POI-Oct-1 V BW for pPsFL-Oct-1; HpFL-Oct-1 I FW and HpFL-Oct-1 I BW for HpFL. Primers used for plasmid constructions are listed in **Supplementary Table 1**.

Analysis of Expression Patterns and Stability of Engineered Proteins

Plasmid pCOLADuet-1, harboring each PsFL or HpFL expression cassette was transformed into E. coli BL21(DE3) cell. E. coli BL21(DE3) cells were grown at 37°C and 200 rpm in a 250-mL baffled flask containing 50 mL of Lysogeny broth (LB) medium (1% tryptone, 0.5% yeast extract, and 1% sodium chloride) and 50 μg/mL of kanamycin. At the mid-exponential growth phase [optical density (OD

was used for plasmid display system on soluble expression at both temperatures. After overnight cultivation, E. coli cells were harvested by centrifugation at 9,300 g for 10 min, resuspended in Bugbuster protein extraction reagent (Novagen), and lysed by orbital shaking for 30 min at 25°C to collect total protein fraction. Samples were centrifuged at 9,300 g for 10 min to separate soluble fraction from the debris (insoluble fraction). The expression level of the target enzyme was analyzed by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The quantification of bands intensity was carried out using the densitometry software (TotalLab 1.01, Non-linear Dynamics Ltd., Newcastle upon, UK).

To evaluate thermal stability of PsFL, E. coli cells expressing WT PsFL and Oct-1-PsFL were cultivated as described above until OD

value reached 0.4–0.6. After 4 h induction at 25°C with 0.1 mM IPTG, E. coli cells were harvested by centrifugation at 9,300 g for 10 to remove IPTG. After IPTG washing, the procedure of centrifugation of culture broth followed by removal of the supernatant containing IPTG, E. coli cells were inoculated into fresh LB medium containing 50 μg/mL of kanamycin, and soluble and insoluble fractions were prepared and analyzed as described above.

In vitro Selection of the Plasmid-Protein Complex

Most experimental processes were performed at 25°C to maintain maximum binding affinity of Oct-1 DBD (Lundback et al., 2000) except for centrifugations which were carried out at 4°C. E. coli cells expressing Oct-1 DBD fusion proteins were cultivated as described above. After cell cultivation, cells were harvested by centrifugation at 9,300 g for 10 min. The pellets were resuspended in 5 mL Bugbuster protein extraction reagent (Novagen), and then the resuspended cells were agitated at 25°C for 30 min. The resulting cell lysates were centrifuged at 9,300 g for 10 min at 4°C to collect the soluble fraction. The supernatants (soluble fraction) were mixed with Ni Sepharose Fast Flow (GE Healthcare), which was pre-equilibrated with an equilibrium.
buffer composed of 0.05 M Tris-HCl and 0.3 M NaCl (pH 8.0). After agitation for 30 min at 25°C, the Ni-NTA resin was washed 5 times with 1 column volume of washing buffer composed of 0.05 M Tris-HCl, 0.3 M NaCl, 10 mM imidazole, and 10% glycerol (pH 8.0). The elution was carried out using 500 µl of elution buffer composed of 0.05 M Tris-HCl, 0.3 M NaCl, and 250 mM imidazole (pH 8.0). From the eluted fractions, protein samples were analyzed by SDS-PAGE on a 12% polyacrylamide (w/v) gel followed by western blotting. Bands of His$_6$-fused Oct-1 on the polyvinylidene difluoride (PVDF) membranes were probed with anti-polyhistidine-peroxidase antibody (Sigma-Aldrich, A7058).

PCR amplification was performed with primer check FW and check BW (Supplementary Table 1) to confirm the presence of correct plasmids. Taq polymerase (Sigma-Aldrich) was used for PCRs to confirm the presence of the plasmid according to the manufacturer’s instruction. The PCR amplification was set as initial denaturation step at 94°C for 1 min, followed by 35 repetitions of the following cycle: denaturation step, 94°C, 30 s; annealing step, 53–58°C, 30 s; and elongation step, 72°C, 1 min/kb. The final step took place at 72°C for 2 min. PCR amplification with primers (check FW and check BW) specific to both pBSx-Oct-1-PsFL and pOct-1-PsFL was used to confirm the presence of the plasmid. Primers used for the check PCR are listed in Supplementary Table 1. The PCR amplified DNA products were analyzed by 1% agarose gel electrophoresis with TAE buffer consisting of 0.05 M Tris-HCl, 0.3 M NaCl, and 250 mM Na$_2$EDTA.

**Analytical Methods**

Cell growth was measured at OD$_{600}$ using a spectrophotometer (BioMate 3S, Thermo Scientific). Lactose, glycerol, 2'-FL, and 3-FL concentrations were determined by a high-performance liquid chromatography (Waters Corporation) equipped with a Rezex ROA-Organic Acid H+ column (Phenomenex, Torrance, CA) for reversed-phase chromatography. Metabolites were separated at isocratic temperature (50°C) and a flow rate of 0.6 mL/min in 0.01 N H$_2$SO$_4$, and then passed through a refractive index detector.

**RESULTS**

**Effects of Oct-1 Dbd Fusion on Soluble and Stable Expression of 1,2-FT From P. saltans (PsFL)**

To investigate the effects of location of Oct-1 DBD and the presence of 3 repeats of the Oct-1 specific DNA binding sequence (3 OBS), various expression systems were designed and their schematic diagrams were shown in Figure 1. The expression system without any tag was used as a control. The recombinant *E. coli* BL21(DE3) containing the various recombinant PsFL genes was grown at 16°C after IPTG induction, and the total and soluble protein fractions were analyzed by SDS-PAGE. The cell lysate after IPTG induction and supernatant after centrifugation of the cell lysate were named as the total and soluble protein fractions, respectively. Protein bands consistent with a molecular weight of the wild type (WT) PsFL (31 kDa) and recombinant PsFLs (50 kDa) were detected (Figures 2A,B). While most WT PsFLs were not expressed as soluble forms, soluble expression of recombinant PsFLs was significantly improved regardless of the location of Oct-1 DBD and the presence of 3 OBS (Figures 2A,B). Densitometric analysis of PsFL bands showed that 76–89% of PsFL was expressed solubly when Oct-1 DBD was attached whereas only 30% of the WT PsFL was expressed as soluble form (Supplementary Figures 3A,B).

We next examined the effects of Oct-1 Dbd fusion on thermal stability of PsFL at 25°C. The induction temperature was increased to 25°C because low induction temperature is not desirable in a large scale fermentation. In addition, we wanted to investigate effects of plasmid display on stability of PsFL at the temperature where difference of stability between WT and recombinant PsFLs became more apparent. When PsFL without any tag was expressed inside the cell and incubated at 25°C for 28 h after induction, the band intensities of the WT PsFL in both total and soluble fractions were decreased continuously over time (Figure 2C and Supplementary Figure 3C). However, when Oct-1 DBD was attached to the N-terminus of recombinant PsFL (Oct-1-PsFL), the PsFL remained soluble and did not show any decrease in band intensity for 28 h after protein expression during initial 8 h (Figure 2D and Supplementary Figure 3D). Attachment of Oct-1 DBD at the C-terminus of PsFL (PsFL-Oct-1) also led to an increase in soluble expression of recombinant PsFL, but to a lesser extent than in the case of N-terminal attachment (Figure 2E and Supplementary Figure 3E).
beneficial effects of Oct-1 DBD fusion on thermal stability of PsFL was further evaluated by comparing expression level of WT PsFL and Oct-1-PsFL after IPTG washing. While soluble expression of WT PsFL was hardly detected after IPTG washing followed by 4 h cultivation, Oct-1-PsFL remained soluble for 6 h (Supplementary Figure 4). These results indicate that IIES via plasmid display allowed proper folding and improved thermostability of the PsFL.

### Binding Ability of Oct-1-PsFL to pCOLADuet-1-Based Plasmids

Interestingly, soluble expression levels of Oct-1-PsFL were almost identical regardless of the presence of 3 OBS in plasmid pCOLADuet-1 (Figure 2A). Therefore, to investigate effects of the presence of 3 OBS on the binding ability of Oct-1 DBD, we performed in vitro selection using His<sub>6</sub>-tag fused Oct-1-PsFL protein along with either plasmid pBSx-Oct-1-PsFL without 3 OBS, or pOct-1-PsFL containing 3 OBS. After cell cultivation and disruption, each His<sub>6</sub>-tag fused Oct-1-PsFL protein was purified by Ni-NTA affinity column chromatography. Western blot analysis clearly indicated that the Oct-1-PsFL was selectively purified using affinity resins with high recovery yields (Figure 3A). Then, possible DNA binding to the purified plasmids was assessed using PCR. After recovering plasmids bound to the PsFL-Oct-1 using a plasmid mini-preparation kit, the presence of plasmids was confirmed by check PCR with primers specific to both pBSx-Oct-1-PsFL and pOct-1-PsFL (Figure 3B). It was confirmed that both the plasmids were recovered in the final elute, suggesting that Oct-1-PsFL can bind to pCOLADuet-1-based plasmids, regardless of the presence of 3 OBS (Figure 3C). The ability of PsFL-Oct-1 to bind to plasmids pBSx-Oct-1-PsFL, pOct-1-PsFL, and even pCOLADuet-1 was verified by electrophoretic mobility shift assay (Figure 3D). We note that 3 OBS-independent binding of PsFL-Oct-1 to pCOLADuet-1-based plasmids is likely due to the presence of the Oct-1 specific DNA binding sequence (5’-ATGCAAAT-3’) in a lacI region and non-specific interaction between plasmid DNA and Oct-1 DBD.

## Whole-Cell Biotransformation With IIES for Efficient Production of 2′-FL and 3-FL

An engineered E. coli capable of producing 2′-FL and 3-FL was constructed by amplifying fluxes in the GDP-L-fucose biosynthetic pathway and by introducing heterologous FTs (Chin et al., 2015; Yu et al., 2018). Specifically, the ΔL M15 BCGW strain was constructed by overexpressing the genes (manB, manC, gmd, and wcaG) coding for the enzymes in the biosynthetic GDP-L-fucose pathway along with attenuation of the lac operon which retains 3% of specific β-galactosidase activity of WT BL21star (DE3). Therefore, the ΔL M15 BCGW strain was chosen as a host strain to produce 2′-FL and 3-FL. Subsequently, the effect of intracellular PsFL immobilization by IIES was investigated with three E. coli ΔL M15 BCGW strains containing the WT PsFL (ΔL M15 BCGW-PsFL) and recombinant PsFLs attached with N-terminal (ΔL M15 BCGW-Oct-1-PsFL) and C-terminal (ΔL BCGW-PsFL-Oct-1) Oct-1 DBD in batch fermentations. Although the cell growth pattern and lactose uptake of the three strains were almost identical, we observed different 2′-FL production patterns of E. coli strains expressing recombinant PsFLs with Oct-1 DBD. The ΔL M15 BCGW-Oct-1-PsFL strain was able to produce 0.36 g/L of 2′-FL with a yield of 0.33 g 2′-FL/g lactose, showing 2.0-fold ($P_{value} = 0.008$) increase of the titer compared to that obtained with the control strain expressing the WT PsFL (Figures 4A,B). Meanwhile, expression of immobilized PsFL with C-terminal Oct-1 DBD (PsFL-Oct-1) resulted in 2.7 ($P_{value} = 0.012$) fold higher 2′-FL titer than that of the control strain (Figure 4C). It is worthy to note that the difference in maximum 2′-FL concentrations reached by E. coli ΔL M15 BCGW strain expressing the PsFL fusion protein with and without 3 OBS was not statistically significant (Supplementary Figure 5).
Collectively from these observations, we concluded that soluble and stable expression of recombinant PsFL by IIES could enable *E. coli* ΔL M15 BCGW background strain to better produce 2′-FL than the control strain.

The positive effects of enzyme immobilization by plasmid display on biotransformation efficiency was also confirmed for 1,3-FT from *H. pylori* (HpFL). In a batch fermentation with the ΔL M15 BCGW-Oct-1-HpFL strain expressing recombinant HpFL attached with N-terminal Oct-1 DBD, 0.3 g/L of 3-FL was produced, corresponding to 2.3 times (*P* _value _ = 0.060) higher than that obtained with the control strain expressing the WT HpFL (ΔL M15 BCGW-HpFL) (Figure 5). However, the engineered strain (ΔL M15 BCGW-HpFL-Oct-1) expressing recombinant HpFL attached with C-terminal Oct-1 DBD could not produce 3-FL in the culture medium (Figure 5C). It is likely that Oct-1 DBD fusion to right after the heptad repeat inhibited dimerization of HpFL molecules which plays an important role in enzyme activity of HpFL. These results indicate that Oc-1 fusion may also increase the stability of oligomeric structure of enzymes when located appropriately.

**DISCUSSION**

Whole-cell biotransformation is a viable alternative for production of proteins and chemicals but has some intrinsic
disadvantages including rapid degradation or aggregation of unstable enzymes, such as FTs. To circumvent this problem, previous studies have reported in vivo immobilization of enzymes using inclusion bodies as a matrix (Steinmann et al., 2010; Han et al., 2017). Multiple heterologous enzymes were successfully immobilized on the surface of inclusion bodies in E. coli while the enzyme activities were maintained (Han et al., 2017). However, this system has two inherent possible risks. First, large production of inclusion bodies might cause burden to the cellular protein synthesis machinery, leading to low yield of soluble expression of target enzymes. Second, the formation of denatured and aggregated target enzymes could be accelerated because the inclusion body-forming protein might interact with the newly synthesized enzymes of interest.

Consequently, we sought to develop a system in which the target enzyme is synthesized and simultaneously bound to plasmid DNA that is stably maintained in E. coli. Several examples which link proteins to plasmid encoding target genes in E. coli cytoplasm have been described recently. DNA binding proteins have been used for plasmid displays include human NF-κB p50 (Speight et al., 2001), yeast GAL4 DNA-binding domain (Choi et al., 2005), zinc finger protein (Rogers et al., 2008), and human Oct-1 DBD (Park et al., 2013). Among these DNA binding proteins, we used the Oct-1 DBD as a DNA binding module due to the following beneficial characteristics: (1) its small size, (2) its short binding site, (3) no requirement of Zn$^{2+}$ for its binding activity, (4) high binding affinity ($K_D = 9 \times 10^{-11}$ M) via cooperative binding, and (5) its high solubility under optimal E. coli growth conditions. Therefore, the highly soluble Oct-1 DBD could be used not only for in vivo enzyme immobilization by plasmid display but also for soluble expression of target enzymes.
Stoichiometric mismatch between the number of BS in plasmids, whose copy number is 30~50/cell, and the number of expressed fusion proteins could lead to limited immobilization of target proteins. In this study, however, substantial amounts of PsFL-Oct-1 were bound to pCOLADuet-1-based plasmids regardless of the presence of 3 OBS. While canonical target DNA binding sequences (5′-ATGCAAAT-3′) is the strongest Oct-1 DBD binding site, the degenerate octamer motif (5′-ATGCAAAT-3′) has ~3-fold lower affinity (Verrijzer et al., 1992). This result is consistent with a previous study reporting that most DNA binding proteins capable of binding to specific DNA sequence also share a considerable affinity for non-specific DNA sequences (Kalodimos et al., 2004). The non-specific binding of Oct-1 DBD to plasmid DNA is one of the beneficial characteristics of IIES using Oct-1 fusion protein, as many commercially available plasmids could be used for plasmid display without introduction of 3 OBS. We also note that some Oct-1 fusion proteins might be immobilized on E. coli genomic DNA because E. coli K-12 strain contains 84 Oct-1 specific DNA binding sequences. Additional experiments are underway.
to elucidate complexes between Oct-1 fusion protein and *E. coli* genomic DNA.

The utility of the IIES via plasmid display was examined in whole-cell biotransformation processes for production of 2'-FL and 3-FL by assuming that immobilization of the PsFL and HpFL on plasmid plays an important role in thermal stability of enzymes. Indeed, functional expression and stability of the enzymes in *E. coli* under 25°C was significantly improved via IIES using plasmids as a matrix. A previous study reported that Oct-1 DBD is highly soluble and stable in *E. coli* (Park et al., 2013). Therefore, we speculate that attachment of Oct-1 DBD led to stabilization of the enzymes not only because the enzymes are immobilized to plasmid DNA but also because the enzymes are stabilized by fusion of highly stable Oct-1 DBD. While Oct-1 DBD attached at either the N-terminal or C-terminal end of PsFL could enhance the biotransformation activity of the engineered *E. coli*, production of 3-FL was not detected when Oct-1 DBD tag was attached to the C-terminal end of HfPL. Even though the mechanism remains to be investigated, we hypothesize that one of the reasons might be due to the presence of unique heptad repeats in C-terminal region of HfPL. These heptad repeats function as a stem, leading to dimerization of HfPL, which is crucial for stability of the enzyme (Yu et al., 2018). Therefore, it was assumed that the Oct-1 DBD got attached to the C-terminal end of HfPL interfered with heptad-repeat-mediated dimerization of HfPL.

In conclusion, *in vivo* immobilization of enzymes via plasmid display allowed soluble and stable expression of the PsFL and HfPL in *E. coli*. As a result, the whole-cell biotransformation efficiency was significantly enhanced by IIES using Oct-1 fusion protein. Our approach could be applicable to other biotransformation processes involving unstable enzymes, whose solubility and stability should be improved for economical production.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher.

**AUTHOR CONTRIBUTIONS**

YP, JS, and D-HK conceived the idea. YP, JS, HK, YJ, HO, YK, JY, JH, MP, and CB designed and performed all experiments. YP, JS, MP, CB, KJ, S-KK, and D-HK analyzed the data. KJ and S-KK provided helpful comments and discussion. D-HK supervised the study. YP, S-KK, and D-HK wrote the manuscript.

**FUNDING**

This study was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (Grant Nos. 2017R1A6A1A03015642 and NRF-2017R1A2B2008211).

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fbioe.2019.00444/full#supplementary-material

**REFERENCES**

Banerji, F., and Mujacic, M. (2004). Recombinant protein folding and misfolding in *Escherichia coli*. Nat. Biotechnol. 22, 1399–1408. doi: 10.1038/nbt1029

Bode, L. (2015). The functional biology of human milk oligosaccharides. Early. Hum. Dev. 91, 619–622. doi: 10.1016/j.earlhumdev.2015.09.001

Chin, Y. W., Kim, J. Y., Lee, W. H., and Seo, J. H. (2015). Enhanced production of 2'-fucosylactose in engineered *Escherichia coli* BL21star(DE3) by modulation of lactose metabolism and fucosyltransferase. J. Biotechnol. 210, 107–115. doi: 10.1016/j.jbiotec.2015.06.431

Choi, Y. H., Kim, J. H., Park, B. S., and Kim, B. G. (2016). Solubilization and iterative saturation mutagenesis of αL,3-fucosyltransferase from *Helicobacter pylori* to enhance its catalytic efficiency. Biotechnol. Bioeng. 113, 1666–1675. doi: 10.1002/bit.25944

Choi, Y. S., Pack, S. P., and Yoo, Y. J. (2005). Development of a plasmid display system using GAL4 DNA binding domain for the in vitro screening of functional proteins. Biotechnol. Lett. 27, 1707–1711. doi: 10.1007/s10529-005-2735-4

Esposito, D., and Chatterjee, D. K. (2006). Enhancement of soluble protein expression through the use of fusion tags. Curr. Opin. Biotech. 17, 553–558. doi: 10.1016/j.copbio.2006.06.003

Han, G. H., Seong, W., Fu, Y., Yoon, P. K., Kim, S. K., Yeom, S. J., et al. (2017). Leucine zipper-mediated targeting of multi-enzyme cascade reactions to inclusion bodies in *Escherichia coli* for enhanced production of 1-butanol. Metab. Eng. 40, 41–49. doi: 10.1016/j.ymben.2016.12.012

Kalodimos, C. G., Biris, N., Bonvin, A. M. J. J., Levandoski, M. M., Guennegues, M., Boelens, R., et al. (2004). Structure and flexibility adaptation in nonspecific and specific protein-DNA complexes. Science 305, 386–389. doi: 10.1126/science.1097064

Klemm, J. D., and Pabo, C. O. (1996). Oct-1 POU domain DNA interactions: cooperative binding of isolated subdomains and effects of covalent linkage. Gene. Dev. 10, 27–36. doi: 10.1101/gad.10.1.27

Lee, W.-H., Han, N.-S., Park, Y.-C., and Seo, J.-H. (2009). Modulation of guanosine 5′-diphosphate-D-mannose metabolism in recombinant *Escherichia coli* for production of guanosine 5′-diphosphate-1-fucose. Bioresour. Technol. 100, 6143–6148. doi: 10.1016/j.biotech.2009.07.035

Lundback, T., Chang, J. F., Phillips, K., Luisi, B., and Ladbury, J. E. (2000). Characterization of sequence-specific DNA binding by the transcription factor Oct-1. Biochemistry 39, 7570–7579. doi: 10.1021/bi000377h

Nomine, Y., Ristiani, T., Laurent, C., Lefevre, J. F., Weiss, E., and Trave, G. (2001). Formation of soluble inclusion bodies by HPV E6 oncoprotein fused to maltose-binding protein. Protein Expres. Purif. 23, 22–32. doi: 10.1006/prep.2001.1451

Park, J. H., Kwon, H. W., and Jeong, K. J. (2013). Development of a plasmid display system with an Oct-1 DNA-binding domain suitable for in vitro screening of functional proteins. J. Biosci. Bioeng. 116, 246–252. doi: 10.1016/j.jbiosc.2013.02.005

Rogers, J., Schoep, R. J., Schroder, O., Clements, T. L., Holland, T. F., Li, J. Q., et al. (2008). Rapid discovery and optimization of therapeutic antibodies against emerging infectious diseases. Protein Eng. Des. Sel. 21, 495–505. doi: 10.1093/protein/gzn027
Sachdev, D., and Chirgwin, J. M. (1999). Properties of soluble fusions between mammalian aspartic proteinases and bacterial maltose-binding protein. *J. Protein Chem.* 18, 127–136. doi: 10.1023/A:1020663903669

Segl, N., Roberts, S. B., and Heintz, N. (1991). Mitotic phosphorylation of the Oct-1 homeodomain and regulation of Oct-1 DNA-binding activity. *Science* 254, 1814–1816. doi: 10.1126/science.1684878

Sheldon, R. A. (2007). Cross-linked enzyme aggregates (CLEAs): stable and recyclable biocatalysts. *Biochem. Soc. Trans.* 35, 1583–1587. doi: 10.1042/BST0351583

Sorensen, H. P., and Mortensen, K. K. (2005). Advanced genetic strategies for recombinant protein expression in *Escherichia coli*. *J. Biotechnol.* 115, 113–128. doi: 10.1016/j.jbiotec.2004.08.004

Speight, R. E., Hart, D. J., Sutherland, J. D., and Blackburn, J. M. (2001). A new plasmid display technology for the in vitro selection of functional phenotype-genotype linked proteins. *Chem. Biol.* 8, 951–965. doi: 10.1016/S1074-5521(01)00066-7

Steinmann, B., Christmann, A., Heiseler, T., Fritz, I., and Kolmar, H. (2010). In vivo enzyme immobilization by inclusion body display. *Appl. Environ. Microb.* 76, 5563–5569. doi: 10.1128/AEM.00612-10

Sun, H. Y., Lin, S. W., Ko, T. P., Pan, J. F., Liu, C. L., Lin, C. N., et al. (2007). Structure and mechanism of *Helicobacter pylori* fucosyltransferase - a basis for lipopolysaccharide variation and inhibitor design. *J. Biol. Chem.* 282, 9973–9982. doi: 10.1074/jbc.M610285200

Thurl, S., Munzert, M., Henker, J., Boehm, G., Muller-Werner, B., Jelinek, J., et al. (2010). Variation of human milk oligosaccharides in relation to milk groups and lactational periods. *Br. J. Nutr.* 104, 1261–1271. doi: 10.1017/S0007114510002072

Verrijzer, C. P., Alkema, M. J., Vanweveren, W. W., Vanleeuwen, H. C., Strating, M. J. J., and Vanderriet, P. C. (1992). The DNA binding specificity of the bipartite POU domain and its subdomains. *Embo. J.* 11, 4993–5003. doi: 10.1002/j.1460-2075.1992.tb05606.x

Xie, T., Wang, A. M., Huang, L. F., Li, H. F., Chen, Z. M., Wang, Q. Y., et al. (2009). Recent advance in the support and technology used in enzyme immobilization. *Afr. J. Biotechnol.* 8, 4724–4733.

Yesudhas, D., Batool, M., Anwar, M. A., Panneerselvam, S., and Choi, S. (2017). Proteins recognizing DNA: structural uniqueness and versatility of DNA-binding domains in stem cell transcription factors. *Genes* 8:192. doi: 10.3390/genes8080192

Yu, J., Shin, J., Park, M., Seydametova, E., Jung, S. M., Seo, J. H., et al. (2018). Engineering of α-1,3-fucosyltransferases for production of 3-fucosyllactose in *Escherichia coli*. *Metab. Eng.* 48, 269–278. doi: 10.1016/j.ymben.2018.05.021

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Park, Shin, Yang, Kim, Jung, Oh, Kim, Hwang, Park, Ban, Jeong, Kim and Kweon. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.